OncoMatch/Clinical Trials/NCT07294625
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
Is NCT07294625 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies LVIVO-TaVec200 product for multiple myeloma.
Treatment: LVIVO-TaVec200 product — This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec200 in the treatment of relapsed/refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: antitumor therapy
Exception: insufficient washout period
Prior antitumor therapy with insufficient washout period
Cannot have received: GPRC5D-targeted therapy
Prior treatment targeting GPRC5D
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07294625 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior antitumor therapy, GPRC5D-targeted therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages